TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.

Trial Details

NCT ID
NCT06487663
Phase
NA
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • TACE with ICI
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Confirmed diagnosis of HCC by histology/ cytology or clinical criteria
  • Sign informed consent
  • When screening for age, the age should be ≥ 18 years old
  • Eligible for TACE treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →